245 related articles for article (PubMed ID: 29596078)
1. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis.
Khan MY; Siddiqui WJ; Alvarez C; Aggarwal S; Hasni SF; Ahmad A; Eisen H
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):847-853. PubMed ID: 29596078
[TBL] [Abstract][Full Text] [Related]
2. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.
Melloni C; Washam JB; Jones WS; Halim SA; Hasselblad V; Mayer SB; Heidenfelder BL; Dolor RJ
Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):47-55. PubMed ID: 25587094
[TBL] [Abstract][Full Text] [Related]
3. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
[No Abstract] [Full Text] [Related]
4. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy.
Jensen BES; Hansen JM; Larsen KS; Junker AB; Lassen JF; Jensen SE; Schaffalitzky de Muckadell OB
Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1118-1125. PubMed ID: 28678044
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
[TBL] [Abstract][Full Text] [Related]
7. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
[TBL] [Abstract][Full Text] [Related]
8. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.
Mandurino-Mirizzi A; Leonardi S; Melloni C
Minerva Endocrinol; 2017 Sep; 42(3):228-237. PubMed ID: 27808485
[TBL] [Abstract][Full Text] [Related]
10. H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review.
Almufleh A; Ramirez FD; So D; Le May M; Chong AY; Torabi N; Hibbert B
Cardiology; 2018; 140(2):115-123. PubMed ID: 29966126
[TBL] [Abstract][Full Text] [Related]
11. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.
Khan SU; Lone AN; Asad ZUA; Rahman H; Khan MS; Saleem MA; Arshad A; Nawaz N; Sattur S; Kaluski E
Cardiovasc Revasc Med; 2019 Dec; 20(12):1125-1133. PubMed ID: 30773427
[TBL] [Abstract][Full Text] [Related]
13. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
Morneau KM; Reaves AB; Martin JB; Oliphant CS
J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Jiang Z; Wu H; Duan Z; Wang Z; Hu K; Ye F; Zhang Z
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):636-41. PubMed ID: 23684576
[TBL] [Abstract][Full Text] [Related]
16. Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease.
He W; Shu X; Zhu E; Deng B; Lin Y; Wu X; Zhou Z; Wang J; Nie R
BMC Cardiovasc Disord; 2021 Feb; 21(1):75. PubMed ID: 33546595
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
[TBL] [Abstract][Full Text] [Related]
19. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
Ortolani P; Marino M; Marzocchi A; De Palma R; Branzi A
J Cardiovasc Med (Hagerstown); 2012 Dec; 13(12):783-9. PubMed ID: 21252697
[TBL] [Abstract][Full Text] [Related]
20. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
